Marie Bouillez - Orgenesis Director
| ORGS Stock | USD 0.50 0.02 3.85% |
Director
Ms. Marie Bouillez is Director of the Company. Ms. Bouillez was Investment Manager at Theodorus since July 2007 an investment fund based in Belgium for startups mainly in the biotech and medical industry. During that time Ms. Bouillez has also been on the Board of Directors of MaSTherCell S.A. our companys now whollyowned subsidiary in Belgium. Since March 2010 Ms. Bouillez was Chief Executive and Managing Director of iTech Incubator SA a Belgian technology incubator. From July 2007 to March 2010 Ms. Bouillez was a consultant for EEBIC Venture SA an investment fund based in Belgium. From October 2003 to July 2007 Ms. Bouillez held various financial and controller positions with Carrefour based in Belgium since 2016.
| Age | 34 |
| Tenure | 8 years |
| Address | 20271 Goldenrod Lane, Germantown, MD, United States, 20876 |
| Phone | 480 659 6404 |
| Web | https://www.orgenesis.com |
Orgenesis Management Efficiency
The company has return on total asset (ROA) of (0.6186) % which means that it has lost $0.6186 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (3.3908) %, meaning that it created substantial loss on money invested by shareholders. Orgenesis' management efficiency ratios could be used to measure how well Orgenesis manages its routine affairs as well as how well it operates its assets and liabilities. Return On Capital Employed is likely to gain to 30.36 in 2024, whereas Return On Tangible Assets are likely to drop (9.74) in 2024. At this time, Orgenesis' Non Currrent Assets Other are comparatively stable compared to the past year. Other Assets is likely to gain to about 1.8 M in 2024, whereas Total Current Assets are likely to drop slightly above 15.1 M in 2024.Similar Executives
| Showing other executives | DIRECTOR Age | ||
| David Welch | Rezolute | 56 | |
| Young Sung | Rezolute | N/A | |
| Antonio Neri | AN2 Therapeutics | 49 | |
| Tae Kim | Rezolute | 34 | |
| Winson Ho | Lixte Biotechnology Holdings | N/A | |
| Kathleen Mullinix | Lixte Biotechnology Holdings | 69 | |
| William Ryan | AN2 Therapeutics | 71 | |
| Philip Palmedo | Lixte Biotechnology Holdings | 80 | |
| Lewis Hay | AN2 Therapeutics | 60 | |
| Yun Yen | Lixte Biotechnology Holdings | N/A | |
| Stephen Forman | Lixte Biotechnology Holdings | N/A | |
| Samir Patel | Rezolute | 46 | |
| Gilbert Labrucherie | Rezolute | 44 | |
| Elizabeth Tallett | AN2 Therapeutics | 67 | |
| Hoyoung Huh | Rezolute | 47 | |
| Yan MBA | Adagene | 49 | |
| George Schaefer | AN2 Therapeutics | 70 | |
| Bahija Jallal | AN2 Therapeutics | N/A | |
| Ramiro Peru | AN2 Therapeutics | 60 | |
| Will Feest | AN2 Therapeutics | N/A | |
| Kerry Clark | AN2 Therapeutics | 63 | |
Management Performance
| Return On Equity | -3.39 | ||||
| Return On Asset | -0.62 |
Orgenesis Leadership Team
Elected by the shareholders, the Orgenesis' board of directors comprises two types of representatives: Orgenesis inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Orgenesis. The board's role is to monitor Orgenesis' management team and ensure that shareholders' interests are well served. Orgenesis' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Orgenesis' outside directors are responsible for providing unbiased perspectives on the board's policies.
| David Sidransky, Director | ||
| Osher Rheinisch, General Officer | ||
| Yaron Adler, Director | ||
| Pierre Lammeretz, Interim Officer | ||
| Neil Reithinger, CFO, Treasurer and Secretary | ||
| Joseph Carpinelli, Chief Octomera | ||
| Etti Hanochi, Director | ||
| Hugues Bultot, Director | ||
| Chris Buyse, Director | ||
| Dan Slonim, COO Israel | ||
| Sarah Ferber, Chief Scientific Officer | ||
| Vincent Vandamme, VP Strategy | ||
| Victor Miller, Chief Officer | ||
| Neil CPA, S CFO | ||
| Shimon Hassin, Chief Officer | ||
| Marie Bouillez, Director | ||
| Efrat Kunik, Chief Officer | ||
| Scott Carmer, CEO of Orgenesis Maryland Inc | ||
| Evan Fishman, Chief Officer | ||
| Guy Yachin, Director | ||
| Vered MSc, CEO Board | ||
| Vered Caplan, Chairman of the Board, Interim President and CEO | ||
| Pr Ferber, Founder Officer |
Orgenesis Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Orgenesis a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -3.39 | ||||
| Return On Asset | -0.62 | ||||
| Operating Margin | (32.13) % | ||||
| Current Valuation | 39.06 M | ||||
| Shares Outstanding | 34.36 M | ||||
| Shares Owned By Insiders | 20.35 % | ||||
| Shares Owned By Institutions | 6.56 % | ||||
| Number Of Shares Shorted | 299.69 K | ||||
| Price To Earning | 7.52 X | ||||
| Price To Book | 1.39 X |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Orgenesis. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in price. For more information on how to buy Orgenesis Stock please use our How to Invest in Orgenesis guide.Note that the Orgenesis information on this page should be used as a complementary analysis to other Orgenesis' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Equity Search module to search for actively traded equities including funds and ETFs from over 30 global markets.
Complementary Tools for Orgenesis Stock analysis
When running Orgenesis' price analysis, check to measure Orgenesis' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Orgenesis is operating at the current time. Most of Orgenesis' value examination focuses on studying past and present price action to predict the probability of Orgenesis' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Orgenesis' price. Additionally, you may evaluate how the addition of Orgenesis to your portfolios can decrease your overall portfolio volatility.
| Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
| USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
| Fundamental Analysis View fundamental data based on most recent published financial statements | |
| Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity | |
| Bonds Directory Find actively traded corporate debentures issued by US companies | |
| Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
| Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
| Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
| Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years | |
| Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. | |
| Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
| Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk |
Is Orgenesis' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Orgenesis. If investors know Orgenesis will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Orgenesis listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.91) | Revenue Per Share 0.018 | Quarterly Revenue Growth (0.99) | Return On Assets (0.62) | Return On Equity (3.39) |
The market value of Orgenesis is measured differently than its book value, which is the value of Orgenesis that is recorded on the company's balance sheet. Investors also form their own opinion of Orgenesis' value that differs from its market value or its book value, called intrinsic value, which is Orgenesis' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Orgenesis' market value can be influenced by many factors that don't directly affect Orgenesis' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Orgenesis' value and its price as these two are different measures arrived at by different means. Investors typically determine if Orgenesis is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Orgenesis' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.